1. Home
  2. BDSX vs VRCA Comparison

BDSX vs VRCA Comparison

Compare BDSX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$14.59

Market Cap

143.2M

Sector

Health Care

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$6.30

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
VRCA
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.2M
137.3M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
BDSX
VRCA
Price
$14.59
$6.30
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$32.50
$17.00
AVG Volume (30 Days)
64.7K
83.6K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,499,000.00
$35,577,000.00
Revenue This Year
$25.26
N/A
Revenue Next Year
$19.15
$94.44
P/E Ratio
N/A
N/A
Revenue Growth
24.08
370.22
52 Week Low
$0.26
$0.49
52 Week High
$20.21
$9.82

Technical Indicators

Market Signals
Indicator
BDSX
VRCA
Relative Strength Index (RSI) 55.64 45.38
Support Level $13.46 $5.13
Resistance Level $16.38 $6.40
Average True Range (ATR) 1.00 0.68
MACD 0.08 -0.17
Stochastic Oscillator 42.83 20.53

Price Performance

Historical Comparison
BDSX
VRCA

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: